KAFOCIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAFOCIN is an oral small-molecule capsule approved by Eli Lilly in 1970 for an undisclosed indication. The mechanism of action and pharmacologic class remain proprietary or undocumented in available sources.
LOE Approaching
As LOE approaches, the brand team is likely in transition planning mode, with reduced headcount and focus shifting toward retention or lifecycle management strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KAFOCIN is a legacy product with zero linked job openings and minimal career development opportunity. Professionals assigned to this brand should view it as a stabilization role or stepping stone to higher-growth therapeutic areas.
Brand ManagerField Sales Representative
Worked on KAFOCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.